7th Gene Therapy for CNS Summit

The 7th Gene Therapy for CNS Summit returns to Boston this October and is the only industry-led conference dedicated to innovating and optimizing gene therapies for CNS disorders. With the changing regulatory landscape, the push to advance through the clinic and be first-in-class with innovative vector delivery methods, and the growing need to develop gene therapies for rare CNS disorders, there is an increasing demand to come together at this dedicated conference.

This summit equips you to streamline your gene therapy development and improve efficacy through in-depth content on:

- Optimizing AAVs, innovating capsids, and developing novel vectors to improve delivery to the brain
- Maximizing translational models to move from discovery to the clinic
- Improving CNS targeting and BBB crossing to reduce toxicities and enhance efficacy
- Streamlining manufacturing processes in early-stage development to prevent delays
- Analyzing different delivery devices to ensure successful gene therapy delivery
- Navigating IND submissions and regulatory guidance to ensure compliance


URLs:
Website: https://go.evvnt.com/3183143-0?pid=2874
Brochure: https://go.evvnt.com/3183143-2?pid=2874

Category: Conferences | Health

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Workshop Day: USD 3597.00,
Academic Pricing - Conference Only: USD 2599.00,
Service Provider Pricing - Conference + Workshop Day: USD 5097.00,
Service Provider Pricing - Conference Only: USD 3699.00

Speakers: Andrew Steinsapir, Acting Chief Technology Officer, Apertura Gene Therapy, Christopher Davis, Manager, Scientific Research, Apertura Gene Therapy, Dhruv Sethi, Senior Director, Obsidian Therapeutics, Dunni Odumosu, Vice President, Head of Global Regulatory Affairs and Sciences, Gene Therapy, BridgeBio Gene Therapy, Eric Kelsic, Chief Executive Officer and Co-Founder, Dyno Therapeutics, James Warren, Senior Vice President - Global Chemistry, Manufacturing and Controls Development, Ultragenyx Pharmaceutical Inc., Jennifer Johnston, Co-Founder and Chief Executive Officer, NysnoBio, John Reece-Hoyes, Senior Director, Head of Vector Biology, Affinia Therapeutics, Ornit Chiba-Falek, Co-Founder, CLAIRIgene, Patrick Hossler, Executive Director, Ultragenyx Pharmaceutical Inc., Ralf Schmid, Associate Director, Novartis AG, Sandra Motas Mallol, Researcher/Project Manager In R AND D Biologics, HIPRA, Shyam Ramachandran, Head of Cluster and Neuroscience, Sanofi, TJ Cradick, Chief Scientific Officer, Principal, Gene Editing Frontiers